登入 / 註冊
微創減重手術 Bariatric & Weight Reduction Service
+ 關注
2013-08-12 - 517觀看次數

公佈播道醫院縮胃手術治療二型糖尿病中期研究結果及 國際糖尿病聯盟利用手術治療二型糖尿病最新指引





  1. 二型糖尿病及體重指數(BMI)>32.5病人應考慮接受手術治療。
  2. 二型糖尿病及體重指數(BMI)>27.5病人可考慮接受手術治療尤其是糖尿病不能以傳統方法控制(HBA1c>7.5%)。
  3. 手術治療二型糖尿病是輔助治療,不應視作取代傳統內科治療的方法。


Report on the use of laparoscopic sleeve gastrectomy at Evangel Hospital for Type II diabetes mellitus and the latest International Diabetes Federation’s recommendations


In Hong Kong, it is estimated that one tenth of the population is suffering from Type II diabetes mellitus (DM), and majority of them are either overweight or obese. While life-style modification and medical therapy is the cornerstone in the management Type II DM, remission of the disease is rarely seen. In a significant proportion of patients (2/3), their compliance to therapy is poor, and the control of Type II DM is far from ideal with increased risks of diabetic complications.

Since its introduction in Asia in 2005, Laparoscopic sleeve gastrectomy (LSG) is becoming the gold standard treatment of obesity in the district. It is a minimally invasive surgical intervention originally designed for the treatment of morbid obesity. It generates weight loss by removing the greater curve of stomach (creating a 150 cc longitudinal gastric reservoir) and diminishing the production of appetite hormone (Ghrelin). The outcome of LSG is apparent and very encouraging with a reported excess body weight loss of 70% in two-year period after surgery in most studies. Recent researches confirmed that in addition to the weight-loss effect, LSG and other similar bariatric gastrointestinal surgery can significantly increase level of incretin (GLP-1) after surgery, which is very beneficial in treating and preventing Type II DM in selected patients. The International Diabetes Federation (IDF) has recently laid down the recommendations of using these kinds of surgical intervention in the treatment of Type II DM in Asia population and are as follows: 

  1. Surgery should be recommended as an appropriate treatment for people with Type II DM with body mass index (BMI) >32.5.
  2. Surgery may be considered as an appropriate treatment for people with Type II DM with BMI >27.5 not achieving recommended treatment target (HbA1c>7.5%) with medical therapies.
  3. Surgery should be considered as a complementary to medical therapies.

With a joint collaboration of specialists from the Evangel Hospital and Qualigenics Diabetes Centre, the first series of LSG in treating Type II DM in Hong Kong was completed. A total of 38 patients had been studied and 51.5 % of patientis were in complete remission after 3-year follow up.



Information provided by Evangel Hospital | 以上資訊由播道醫院提供

Copyright 2024© 版權屬哈利路亞國際事工有限公司所有.